Arrhythmias, CardiacSMARTTELNCT04609436
SmartCardia Wireless Recorder as a Telemetry System
An observational study of Arrhythmias, Cardiac and Monitoring, run by University Hospital Freiburg at 1 site in Switzerland.
Trial summary
Patients hospitalized at the clinic Cecil who need telemetry will be monitored for 48 hours with the SmartCardia system in addition to conventional monitoring. Read more about this study
- Who is it for?
- Ages 18 to 100 years
- Conditions the study is for
- Arrhythmias, Cardiac, Monitoring
- What is being tested?
- Cardiac monitoring with the wireless device "SmartCardia"
- Type of treatment
- Medical device
- How many people
- 50 participants
- Where
- 1 siteSwitzerland
- Study dates
- 1 Feb 2020to 1 Feb 2023
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 100 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: Patients requiring cardiac monitoring after heart surgery will be included
Who may be able to join
- Any patient who needs to be monitored for at least 48 hours can be included in the study.
Who cannot join
- allergic to sticking plaster
- refusing to participate will be excluded from the study.
- planed MRI examination
- open wound
- Severe thorax deformity making recording not possible.
Trial locations and contacts
1 site in 1 country.
About this study
Official title: Clinical Use of the SmartCardia Wireless Recorder as a Telemetry System in Patients Hospitalized Outside Intensive Care (the SMART-TEL Study Trial)
Patients hospitalized at the clinic Cecil who need telemetry will be monitored for 48 hours with the SmartCardia system in addition to conventional monitoring.
Read the detailed description
Cardiac arrhythmias, such as atrial fibrillation or ventricular arrhythmias, are often asymptomatic and sometimes associated with an adverse event, such as a stroke or syncope. Telemetry monitoring in hospitals, 24 hours a day, is the most used method for detecting these cardiac arrhythmias, especially after major surgery or cardiac surgery. Currently this cardiac monitoring is ensured by a system called telemetry, a kind of box connected to 4 electrodes stuck on the patient's chest. Information is continuously transmitted to a screen located in the nurses' room, which is supposed to watch the screen continuously. There are also alarms that can be triggered when an arrhythmia occurs. In practice, it is found that very often the electrodes are disconnected for practical reasons (patient going to the toilet for example) or accidentally. The alarms are not always observed because they very often sound badly. In addition, 24-hour telemetric monitoring sometimes fails to detect the culprit arrhythmia. Event monitoring significantly increases performance of the system. It has recently been shown that the ZIO patch (iRhythm Technologies Ltd.), a wireless electrocardiography allows te detection of arrhythmias in children, confirming the usefulness of such devices in daily practice.
3.2 Investigational product and indication.
The SmartCardia patch (SmartCardia, EPFL (Ecole polytechnique fédérale Lausanne) Innovation Park, Lausanne, Switzerland) is a lightweight wireless ECG device (Figure 1) mounted on a patch with waterproof properties. The device is completely wireless and has no external connection wires. It allows patients to go about their daily activities with minimal disruption. The SmartCardia system allows in hospital patients monitoring, and corresponds to telemetry, functioning as 24 hour cardiac monitoring. The device is placed on the upper left part of the patient's chest (Figure 2). The patch can wirelessly communicate the data to a screen that will display it live. In addition, this data will be stored in the recording device and in the cloud. Once monitoring is complete, the data remains stored in the cloud and is available to physicians. During the recording, at any time, the doctor can be connected and interrogate the device in order to visualise the arrhythmias of his patient. The first studies using this device in the clinic have recently been published with very encouraging results. The device is classified in category A (Swiss government office decision attached). Previous trials with this device have shown its clinical usefulness in the intensive care unit and in daily practice. The device is actually proposed and used by many cardiologists as an alternative to the conventional Holter monitoring system. The goal of the present trial is mainly to confirm tha ability of this device to be used as a telemetry system on the ward in order to overpass the inconvenience of the actual system related to permanent cable connections with the risk of disconnexion and lost of monitoring. This trial is mainly a confirmation of that the device is a valuable option for telemetry.
The device used for this trial is the one certified by Swissmedics with UE (Union Européenne) certification
3.3 Pre-clinical evidence
The benefits of using such a type of monitoring are obvious. The patient is autonomous in his movements. The risks associated with disconnection are nonexistent. In addition, the doctor can consult the patient's data directly at any time. Finally, the data are stored in the cloud and archiving is made easier. The only risk associated with this system is an allergy to the adhesive patch. In view of the potential benefits expected from the use of this system, it is easy to understand that the study is justified. It should be kept in mind that the conventional system also has limits essentially linked to the risk of cable disconnection.
The risk linked to a bad registration of the SmartCardia system which would generate an incorrect treatment does not exist, because the clinical decision will be taken by the doctor and based only on the data provided by conventional monitoring.
Previous trials have shown the accuracy and advantages of this new wireless recorder. The system is already used in the daily practice in several countries as an alternative to conventional Holter monitoring.
3.4 Explanation for choice of comparator
The new system will be used in parallel with the conventional monitoring system. It is obvious that the conventional monitoring system should be used as the gold standard.
3.5 Risks/Benefit
There are no risks related to the use of this new device as therapeutic decision will be based only the recording of the conventional system. Benefits could be expected in the future since wireless system are preferred by the patients as demonstrated in previous trials comparing Holter monitoring and the SmartCardia device.
3.6 Justification of choice of study population
Patients after cardiac surgery are usually monitored for a few days when they are back to the ward. It is obvious that they are the cohort of choice for such monitoring since they require it anyway.
- Conditions
- Arrhythmias, Cardiac, Monitoring
- Being tested
- Cardiac monitoring with the wireless device "SmartCardia"
- Keywords
- non invasive monitoring
- Medical subject headings
- Arrhythmias, Cardiac
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Cardiac monitoring with the wireless device "SmartCardia"Device
Monitoring of arrhythmia with a wireless device (SmartCardia)
| Study group | Role | What they receive |
|---|---|---|
| Single arm | This is a single arm trial. The patient is his own control. Receives: Device: Cardiac monitoring with the wireless device "SmartCardia" |
What is being measured
The primary outcome is the main question the study is designed to answer.
Arrhythmia counting after heart surgery
The primary outcome is to detect supra-ventricular and ventricular arrhythmias following cardiac surgery. The following data will be reported:
- Number per minute of ventricular and/or supra-ventricular extrasystoles,
- Number per minute of supra-ventricular and/or ventricular doublets,
- Number per minute of supra-ventricular and/or ventricular triplets,
- Number of episodes/24 hours of supra-ventricular and/ot of ventricular tachycardia (VT) will be measured,
- Number of episodes of atrial fibrillation will be measured.
- Number of pause exceeding 2 seconds will be reported.
Measured: 48 hours following cardiac surgery part of 10 days of hospitalization post surgery.
Secondary outcomes (4)
Duration of arrhythmias after heart surgery
- Duration of the arrhythmia will be reported in seconds.
- Duration of episodes of atrial fibrillation will be reported in seconds.
Measured: 48 hours following cardiac surgery part of 10 days of hospitalization post surgery.
Noise analysis
Noise will also be analysed. Noise is defined as parts of the ECG signal that cannot be analysed by technicians, such as a movement artefact or muscle activity in the ECG signal. It will be measured in dividing the number of uninterpretable signals by the number of interpretable signals and reported as a percentage. This noise exists both with the SmartCardia system and with the system currently used, described as the "gold standard".
- The number of episodes/24 h of noise will be reported.
Measured: 48 hours following cardiac surgery part of 10 days of hospitalization post surgery.
Incidence of noise
1.The number of episodes of noise will be counted.
Measured: 48 hours following cardiac surgery part of 10 days of hospitalization post surgery.
Percentage of episodes of noise.
- The percentage of noise episodes and normal detected beats will calculated in percent.
Measured: 48 hours following cardiac surgery part of 10 days of hospitalization post surgery.
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted30 Oct 2020
- Study start1 Feb 2020
- Primary completion1 Mar 2020
- Study completion1 Feb 2023
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Arrhythmias, CardiacStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Case only
- Time perspective
- Prospective
- Enrolment
- 50 participants (actual)
Sponsor and investigators
- Lead sponsor
- University Hospital Freiburg
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Stephane Cook, University Hospital Freiburg
- Investigators
- Jean-Jacques Goy, MD, Principal investigator, Hirslanden Cecil
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT04609436
- Sponsor's protocol ID
- CER 2020-0141
- Acronym
- SMARTTEL
- Status last verified
- Dec 2023
- First submitted
- 29 Sep 2020
- Last updated
- 8 Dec 2023
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 8 Dec 2023. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Clinical Use of the SmartCardia Wireless Recorder as a Telemetry System in Patients Hospitalized Outside Intensive Care (the SMART-TEL Study Trial)
- ClinicalTrials.gov ID
- NCT04609436
- Acronym / sponsor ID
- SMARTTEL / CER 2020-0141
- Conditions
- Arrhythmias, Cardiac, Monitoring
- Keywords
- non invasive monitoring
- Study type
- Observational
- Recruitment status
- Completed
- Enrolment
- 50 participants (actual)
- Lead sponsor
- University Hospital FreiburgUniversity, hospital or other
- Study start
- 1 Feb 2020 (actual)
- Primary completion
- 1 Mar 2020 (actual)
- Study completion
- 1 Feb 2023 (actual)
- First posted
- 30 Oct 2020 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Patients hospitalized at the clinic Cecil who need telemetry will be monitored for 48 hours with the SmartCardia system in addition to conventional monitoring.
Detailed description
Cardiac arrhythmias, such as atrial fibrillation or ventricular arrhythmias, are often asymptomatic and sometimes associated with an adverse event, such as a stroke or syncope. Telemetry monitoring in hospitals, 24 hours a day, is the most used method for detecting these cardiac arrhythmias, especially after major surgery or cardiac surgery. Currently this cardiac monitoring is ensured by a system called telemetry, a kind of box connected to 4 electrodes stuck on the patient's chest. Information is continuously transmitted to a screen located in the nurses' room, which is supposed to watch the screen continuously. There are also alarms that can be triggered when an arrhythmia occurs. In practice, it is found that very often the electrodes are disconnected for practical reasons (patient going to the toilet for example) or accidentally. The alarms are not always observed because they very often sound badly. In addition, 24-hour telemetric monitoring sometimes fails to detect the culprit arrhythmia. Event monitoring significantly increases performance of the system. It has recently been shown that the ZIO patch (iRhythm Technologies Ltd.), a wireless electrocardiography allows te detection of arrhythmias in children, confirming the usefulness of such devices in daily practice.
3.2 Investigational product and indication.
The SmartCardia patch (SmartCardia, EPFL (Ecole polytechnique fédérale Lausanne) Innovation Park, Lausanne, Switzerland) is a lightweight wireless ECG device (Figure 1) mounted on a patch with waterproof properties. The device is completely wireless and has no external connection wires. It allows patients to go about their daily activities with minimal disruption. The SmartCardia system allows in hospital patients monitoring, and corresponds to telemetry, functioning as 24 hour cardiac monitoring. The device is placed on the upper left part of the patient's chest (Figure 2). The patch can wirelessly communicate the data to a screen that will display it live. In addition, this data will be stored in the recording device and in the cloud. Once monitoring is complete, the data remains stored in the cloud and is available to physicians. During the recording, at any time, the doctor can be connected and interrogate the device in order to visualise the arrhythmias of his patient. The first studies using this device in the clinic have recently been published with very encouraging results. The device is classified in category A (Swiss government office decision attached). Previous trials with this device have shown its clinical usefulness in the intensive care unit and in daily practice. The device is actually proposed and used by many cardiologists as an alternative to the conventional Holter monitoring system. The goal of the present trial is mainly to confirm tha ability of this device to be used as a telemetry system on the ward in order to overpass the inconvenience of the actual system related to permanent cable connections with the risk of disconnexion and lost of monitoring. This trial is mainly a confirmation of that the device is a valuable option for telemetry.
The device used for this trial is the one certified by Swissmedics with UE (Union Européenne) certification
3.3 Pre-clinical evidence
The benefits of using such a type of monitoring are obvious. The patient is autonomous in his movements. The risks associated with disconnection are nonexistent. In addition, the doctor can consult the patient's data directly at any time. Finally, the data are stored in the cloud and archiving is made easier. The only risk associated with this system is an allergy to the adhesive patch. In view of the potential benefits expected from the use of this system, it is easy to understand that the study is justified. It should be kept in mind that the conventional system also has limits essentially linked to the risk of cable disconnection.
The risk linked to a bad registration of the SmartCardia system which would generate an incorrect treatment does not exist, because the clinical decision will be taken by the doctor and based only on the data provided by conventional monitoring.
Previous trials have shown the accuracy and advantages of this new wireless recorder. The system is already used in the daily practice in several countries as an alternative to conventional Holter monitoring.
3.4 Explanation for choice of comparator
The new system will be used in parallel with the conventional monitoring system. It is obvious that the conventional monitoring system should be used as the gold standard.
3.5 Risks/Benefit
There are no risks related to the use of this new device as therapeutic decision will be based only the recording of the conventional system. Benefits could be expected in the future since wireless system are preferred by the patients as demonstrated in previous trials comparing Holter monitoring and the SmartCardia device.
3.6 Justification of choice of study population
Patients after cardiac surgery are usually monitored for a few days when they are back to the ward. It is obvious that they are the cohort of choice for such monitoring since they require it anyway.
Study design
- Observational model
- Case only
- Time perspective
- Prospective
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| Single arm | – | Device: Cardiac monitoring with the wireless device "SmartCardia"This is a single arm trial. The patient is his own control. |
Who may qualify
- Ages
- 18 to 100 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- Patients requiring cardiac monitoring after heart surgery will be included
Key inclusion criteria (1 listed)
- Any patient who needs to be monitored for at least 48 hours can be included in the study.
Key exclusion criteria (5 listed)
- allergic to sticking plaster
- refusing to participate will be excluded from the study.
- planed MRI examination
- open wound
- Severe thorax deformity making recording not possible.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Cardiac monitoring with the wireless device "SmartCardia"Monitoring of arrhythmia with a wireless device (SmartCardia) | Device | Single arm |
Primary outcome
Arrhythmia counting after heart surgery
Time frame: 48 hours following cardiac surgery part of 10 days of hospitalization post surgery.
The primary outcome is to detect supra-ventricular and ventricular arrhythmias following cardiac surgery. The following data will be reported: 1. Number per minute of ventricular and/or supra-ventricular extrasystoles, 2. Number per minute of supra-ventricular and/or ventricular doublets, 3. Number per minute of supra-ventricular and/or ventricular triplets, 4. Number of episodes/24 hours of supra-ventricular and/ot of ventricular tachycardia (VT) will be measured, 5. Number of episodes of atrial fibrillation will be measured. 6. Number of pause exceeding 2 seconds will be reported.
4 secondary outcomes
Duration of arrhythmias after heart surgery
Time frame: 48 hours following cardiac surgery part of 10 days of hospitalization post surgery.
Noise analysis
Time frame: 48 hours following cardiac surgery part of 10 days of hospitalization post surgery.
Incidence of noise
Time frame: 48 hours following cardiac surgery part of 10 days of hospitalization post surgery.
Percentage of episodes of noise.
Time frame: 48 hours following cardiac surgery part of 10 days of hospitalization post surgery.
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 8 Dec 2023.
- Individual participant dataSharing planned: No
Related trials for Arrhythmias, Cardiac
RecruitingObservational study
BOdygUardian MOnitoriNg for ReCurrencE of AF
Atrial Fibrillation (AF)
Active, not recruiting
Safety and Efficacy of Conscious Sedation Versus General Anesthesia in Pulsed-Field Ablation for Paroxysmal Atrial Fibrillation
Atrial Fibrillation (Paroxysmal)
Active, not recruitingObservational study
Resumption of Anticoagulation After Major Gastrointestinal Bleeding in Patients With Atrial Fibrillation
Atrial Fibrillation (AF), Gastrointestinal Bleeding
Recruiting
A Comparison of Pulsed Field Ablation (PFA) vs Cryoablation for Atrial Fibrillation Under Deep Sedation
Atrial Fibrillation (AF)
Not yet recruiting
CATCH AF - Atrial Fibrillation Detection in Cryptogenic Stroke
Atrial Fibrillation (AF)
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Jean-Jacques Goy, MD principal investigator
Hirslanden Cecil
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Arrhythmias, Cardiac and Monitoring, run by University Hospital Freiburg at 1 site in Switzerland.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 5 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 8 Dec 2023. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Switzerland. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Arrhythmia counting after heart surgery (time frame: 48 hours following cardiac surgery part of 10 days of hospitalization post surgery.). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 8 Dec 2023.